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a b s t r a c t
This review summarized limited information known about periprocedural antithrombotic
therapy before, during and immediately after percutaneous catheter-based thrombectomy
for acute ischemic stroke. Very few data on this topic were published so far. In general, rtPA
should be used upfront whenever clinically clearly indicated (0–3 h from stroke onset,
absence of contraindications) irrespective of subsequent mechanical thrombectomy. If
mechanical treatment follows after thrombolysis, neither anticoagulation, nor antiplatelet
agents should be used in the acute phase. No data exist about the periprocedural use of
anticoagulation or antiplatelet therapy in patients who cannot receive ﬁbrinolysis and
undergo direct mechanical thrombectomy alone. Most centers use no or very low dose
heparin and a single dose of aspirin.
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Interventional therapy of acute ischemic stroke is slowly
emerging as an alternative treatment option besides throm-
bolytic therapy. Frequently both treatments are combined
(‘‘bridging’’ thrombolysis or intraarterial ‘‘local’’ thromboly-
sis). Among various technical approaches to interventional
therapy thrombectomy with stent-retrievers dominates after
2012, when the ﬁrst devices (Solitaire® and Trevo®) were
approved by the FDA. There is very limited information
available on periprocedural antiplatelet or anticoagulant
therapy before/during/after catheter-based thrombectomy
(CBT). The aim of this article is to summarize the available
published information on this topic.
What is (not) mentioned in the US guidelines?
Possibly the most comprehensive document on this subject
– the American guidelines for the management of acute
stroke [1] – describes the reperfusion strategies and the use
of anticoagulant and antiplatelet agents as the primary
therapy for stroke, but not as periprocedural therapy during
CBT. There are 22 contraindications for the use of throm-
bolysis in acute stroke within 0–3 h from stroke onset, 27
contraindications for its use between 3 and 4.5 h and
intravenous (systemic) thrombolysis is not recommended
after 4.5 h (Table 1). Among important contraindications is
very high blood pressure (due to increased risk of intracra-
nial bleeding). Arterial blood pressure should be below 180/
105 mmHg before iv. rtPA is initiated. Intravenous rtPA in
the dose of 0.9 mg/kg (max. 90 mg total) is indicated for
selected patients (without contraindications) who can beTable 1 – Contraindications for thrombolytic therapy of acute s
Absolute contraindications 
Signiﬁcant head trauma or prior stroke in previous 3 months O
sp
Symptoms suggest subarachnoid hemorrhage Pr
Arterial puncture at noncompressible site in previous 7 days Se
History of previous intracranial hemorrhage M
Intracranial neoplasm, arteriovenous malformation, or
aneurysm
Re
pr
Recent intracranial or intraspinal surgery Re
Elevated blood pressure (systolic >185 mm Hg or diastolic
>110 mm Hg)
A
Active internal bleeding Se
Acute bleeding diathesis T
Platelet count <100,000/mm3 H
Heparin received within 48 h, resulting in abnormally elevated
aPTT greater than the upper limit of normal
Im
th
Current use of anticoagulant with INR >1.7 or PT >15 s
Current use of direct thrombin inhibitors or direct factor Xa
inhibitors with elevated sensitive laboratory tests (such as
aPTT, INR, platelet count, and ECT; TT; or appropriate factor
Xa activity assays)
Blood glucose concentration <2.7 mmol/L
CT demonstrates multilobar infarction (hypodensity >1/3
cerebral hemisphere)treated within 3 h of stroke onset (IA recommendation) or
within 3–4.5 h (IB recommendation). Interestingly, rtPA has
FDA approval only for the use within 0–3 h from stroke
onset and not for more delayed use. In other words, iv.
thrombolysis between 3 and 4.5 h from stroke onset is
recommended by the guidelines, but not approved by the
FDA. Similarly, intraarterial rtPA is not approved by FDA, but
was frequently used as part of acute intervention prior to
the era of stent-retrievers. Nowadays, when stent-retrievers
are much faster and much more effective, i.a. use of rtPA
is reserved only for patients with more distal occlusions,
not accessible with stent-retrievers. The guidelines also
recommend, that patients eligible for rtPA should receive iv.
rtPA even if endovascular treatment is considered (IA
recommendation). The total ischemic time (stroke onset –
reperfusion) is even more critical in acute stroke than in
acute myocardial infarction. Thus, the guidelines recom-
mend door-to-needle time <60 min (from hospital arrival to
initiation of rtPA infusion) as an important parameter for
quality control.
Thrombectomy devices can be useful in achieving recana-
lization alone or in combination with pharmacological
ﬁbrinolysis (IIaB recommendation). Mechanical thrombecto-
my is reasonable in patients who have contraindications to the
use of intravenous ﬁbrinolysis (IIaC recommendation). As
mentioned above, no information is given in these guidelines
about the use of anticoagulants during CBT in patients with
contraindications for thrombolysis. In general, urgent antic-
oagulation with the goal of preventing early recurrent stroke
or improving stroke outcomes or for the management of non-
cerebrovascular conditions is not recommended due to the
risk of serious intracranial hemorrhage (IIIA recommenda-
tion). Anticoagulant therapy within 24 h after rtPA is not
recommended (IIIB).troke [1].
Relative contraindications
nly minor or rapidly improving stroke symptoms (clearing
ontaneously)
egnancy
izure at onset with postictal residual neurological impairments
ajor surgery or serious trauma within previous 14 days
cent gastrointestinal or urinary tract hemorrhage (within
evious 21 days)
cent acute myocardial infarction (within previous 3 months)
ged >80 years
vere stroke (NIHSS > 25)
aking an oral anticoagulant regardless of INR
istory of both diabetes and prior ischemic stroke
aging evidence of ischemic injury involving more than one third of
e MCA territory
Table 2 – Antithrombotic therapy in acute stroke.
Medical only management of acute ischemic
stroke (initial 24 h)
Periprocedural therapy before/during CBT
rtPA Yes: within 0–3 (4.5) hours from stroke onset if no
contraindication is present
Yes: as bridging therapy or as intraarterial therapy
(i.a. not approved by FDA).
Heparin No role for acute anticoagulation. Not for patients who received rtPA.
Heparin use for patients treated with mechanical
thrombectomy (without lytics) should be subject to
research.
Aspirin Not as acute treatment, not within 24 h after rtPA. Not for patients who received rtPA.
Yes as oral secondary prevention within 24–48 h. ASA use for patients treated with mechanical
thrombectomy (without lytics) should be subject to
research.
Clopidogrel Limited information, further research needed. No information.
GPIIb/IIIa inhibitors No. No.
Modified from [1].
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use of antiplatelet agents. Acetylsalicylic acid (ASA) is not
recommended as a substitute for other acute interventions
(IIIB), ASA is not recommended as adjunctive therapy within
24 h of iv. rtPA (IIIC). Oral ASA should be initiated within
24–48 h after stroke onset (IA recommendation). The useful-
ness of clopidogrel in acute ischemic stroke is not well
established and further research is required (IIbC). Intravenous
GPIIb/IIIa inhibitors are not recommended (IIIB). Table 2 shows
extracted message from the AHA/ASA guidelines on antith-
rombotic therapy.
Similar to AHA/ASA guidelines, no information about
periprocedural anticoagulation or antiplatelet treatment is
provided in the important multisociety consensus paper on
catheter-based interventions in acute stroke [2].
Periprocedural therapy in published trials and
registries
One of the largest European registries – the Bernese registry –
included 227 patients treated during one year period with CBT.
Symptomatic intracranial bleeding occurred in 9.7% and
asymptomatic in 15%. Unfortunately, no information about
periprocedural antithrombotic medication was provided [3].
The recent landmark Dutch randomized trial MR CLEAN
enrolled 500 patients, 233 of them randomized to mechanical
intervention. Thrombolysis was used before randomization in
89% of them, but no information about periprocedural
anticoagulant of antiplatelet medication was given [4].
A small single center registry of 23 consecutive cases of
emergency carotid stenting followed by mechanical thromb-
ectomy found successful carotid stenting in all cases, and
establishment of TICI ﬂow 2a/2b/3 in 91%. Symptomatic
intracranial hemorrhage (SICH) occurred in 5/23 patients
(22%). Of 13 patients receiving an intravenous loading dose of
abciximab during the procedure, 4/13 had SICH (31%)
compared with 1/10 (10%) of those who did not. Of seven
patients who received intravenous tissue plasminogen
activator prior to the procedure, none had SICH. 90-day
mortality was 9/23 (39%). All patients who had SICH wereabove the median age [5]. A large single center registry of
471 patients undergoing carotid surgery compared outcomes
after ASA alone vs. after ASA + clopidogrel [6]. When divided
by indication, there was an increased long-term mortality rate
in patients with asymptomatic carotid disease receiving
dual antiplatelet therapy as compared with aspirin alone (47%
vs. 40%; P = .05), while patients with symptomatic carotid
disease had a nonsigniﬁcant decrease in all-cause mortality if
they received dual antiplatelet therapy (38% vs. 39%; P = .53).
The most recent study [7] on retrievable stent also did not
describe details of antithrombotic regimen. The text merely
mentioned ‘‘Lytic administration and/or systemic antic-
oagulation were performed at the discretion of the treating
physician.’’ In the TREVO study it was recommended, that
administration of anticoagulants and antiplatelets be sus-
pended for 24 h post-thrombectomy in patients who were not
in direct need of these agents. Heparin use within previous
48 h with aPTT >2 times normal was even an exclusion
criterion. Intravenous thrombolysis was used in 60% of
patients prior to the endovascular procedure. Periprocedural
antithrombotic treatment included i.a. rtPA in 10% and GP
IIb/IIIa inhibitors in 5% [8]. One study [9] used neither i.v.
heparin nor intra-arterial ﬁbrinolytics at any time during the
mechanical thrombectomy procedure, even if the recanali-
zation attempt was unsuccessful. When stent placement was
needed, antiplatelet management consisted of 500 mg of
aspirin i.v. during the procedure, and double antiplatelet
was discussed after the 24-h CT control in view of any serious
hemorrhagic complications. Patients treated by direct CBT in
a Turkish study [10] received 100 mg ASA before CBT in the
emergency department. During interventional stroke proce-
dure, 2000 units of bolus heparin were given routinely. No
further antiplatelet or heparin was administered within 24 h
of procedure. A CT or MRI was performed 24 h after the
procedure. If no hemorrhage was present, aspirin 300 mg/day
was given.
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